Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer
Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC). In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.
Achilles’ precision tumour-infiltrating lymphocyte (TIL) therapy uses cutting edge genomics to selectively target patient specific clonal neoantigens – targets which are believed to be present on all tumour cells – this approach has the potential to transform the treatment of cancer.
The CHIRON study is an open-label, multi-centre Phase I/II trial evaluating the safety, tolerability and clinical activity of cNeT therapy as a single dose in adult patients with advanced metastatic NSCLC. The trial is expected to recruit approximately 40 patients and report interim data in the first half of 2021. Recruitment is ongoing across sites in the UK, with additional sites to open in the US and Europe. Link to Study.
“The cNeT dosing of the first patient with NSCLC marks another important milestone for Achilles. Our opportunity to serve patients is tremendous as NSCLC remains one of the most prevalent and poorly served of the solid tumours,” said Dr Iraj Ali, CEO of Achilles Therapeutics. “As with our melanoma study, the CHIRON study is an entirely personalised cell therapy designed to be exquisitely specific and effective and has the potential to help us fundamentally change how certain cancers are treated.”
“We have been working closely with the Achilles team to design and set up this study across the UK, and are delighted to be dosing the first NSCLC patient with this innovative experimental cell therapy here at University College London Hospital (UCLH), the lead clinical site,” said Dr Martin Forster, Associate Professor in Medical Oncology and Study Chief Investigator.
Achilles is developing personalised T cell therapies for solid tumours targeting clonal neoantigens: protein markers unique to each patient that are present on the surface of all cancer cells. Using its PELEUS™ bioinformatics platform, Achilles can identify clonal neoantigens from each patient’s unique tumour profile which are present on every cancer cell. Achilles uses its proprietary process to manufacture T cells (cNeT) which exquisitely target a specific set of clonal neoantigens in each patient. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, reduces the risk that new mutations can induce immune evasion and therapeutic resistance, and allows individualised treatments to target and destroy tumours without harming healthy tissue.